Omnicell (NASDAQ:OMCL) Releases Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its first quarter 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.150-0.250 for the period, compared to the consensus estimate of 0.210. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $260.2 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Analyst Ratings Changes

Several brokerages recently issued reports on OMCL. Wells Fargo & Company cut their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Benchmark reiterated a “buy” rating and issued a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. dropped their price objective on Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Bank of America dropped their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Finally, StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a report on Monday. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $51.00.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $35.35 on Friday. The firm’s 50-day simple moving average is $39.16 and its 200 day simple moving average is $42.64. The stock has a market cap of $1.65 billion, a P/E ratio of 130.93, a P/E/G ratio of 7.53 and a beta of 0.85. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.75.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Equities analysts expect that Omnicell will post 1.09 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.